GC LabCell Taps Alliances In Bid For Lead NK Cell Position

Links With Artiva In US

 
• By Jung Won Shin
  
Generate a summary of this article
Listen to this article
Beta

After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.

NK Cell
Lead NK Cell Therapy Pipeline Begins US Clinical Trials • Source: Shutterstock

Over the past decade, GC LabCell has grown into a cell therapy development specialist from being focused previously mainly on clinical laboratory services. The company, which is emerging as a leader in the field of natural killer (NK) cell biology, has been concentrating on optimizing NK cell production and therapeutic applications and believes it is now ready to compete with global rivals.

GC LabCell is the allogeneic cell therapy affiliate of leading South Korean biopharma group GC, formerly known as Green...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cell Therapies

Progress Or Hype? A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Japan Cell Therapy Hopes Hit By HeartSheet Full Approval Hurdles

 
• By Lisa Takagi

Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: global CEO remuneration; another late-stage loss for Merch KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.

Bayer's Bets In Parkinson's Start To Bear Fruit

 
• By Kevin Grogan

The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.

More from Advanced Therapies

spo

Akash test for clone

Test article to check the clone issue

Live test

 
• By Mary Jo Laffler

Progress Or Hype? A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.